Diana Mitrea (@diamitrea) 's Twitter Profile
Diana Mitrea

@diamitrea

ID: 1507422959236964363

calendar_today25-03-2022 18:26:20

79 Tweet

87 Followers

86 Following

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

In a recent Pharmafocus interview, Dewpoint CEO Ameet Nathwani shares his thoughts on the current landscape of diabetes therapies. Read to learn how #condensates play a role in disease progression and may be targeted with a new generation of therapeutics: pharmafocus.com/collections/ph…

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

See a promising example of a condensate-modifying drug that inhibits tumor growth in the recent nature paper from The Conrad Lab showing FSP1 inhibition via relocalization to condensates, which induces ferroptosis in cancer cells. nature.com/articles/s4158…

Kriwacki Lab (@kriwacki) 's Twitter Profile Photo

Published today in Nature Communications - our efforts to better understand the prevalence of biomolecular condensate formation amongst fusion oncoproteins found in a range of diverse cancers. rdcu.be/dneM5

Diana Mitrea (@diamitrea) 's Twitter Profile Photo

Congratulations team on this exciting and valuable resource, demonstrating the broad implications of aberrant condensation in oncology!

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Dewpoint co-founder Richard Young, board member Regina Barzilay, head of Cancer Biology Ann Boija & team published in Nature Chemical Biology how deep learning predicts specific partitioning of small molecules in #condensates with distinct chemical environments: nature.com/articles/s4158…

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

In the last 5 years, Dewpoint has made huge progress evolving and applying the science of condensates towards therapeutic discovery. Read our latest article to hear more from our CSO Isaac Klein bit.ly/45YJ9mn

In the last 5 years, Dewpoint has made huge progress evolving and applying the science of condensates towards therapeutic discovery. Read our latest article to hear more from our CSO <a href="/IsaacAKlein/">Isaac Klein</a> bit.ly/45YJ9mn
Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Advance Oncology Pipeline - Read more: dewpointx.com/dewpoint-thera…

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Advance Oncology Pipeline - Read more: dewpointx.com/dewpoint-thera…
Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

At last week’s annual ASHG meeting, Dewpoint scientist Ruoyu Tian shared our advances in identifying the role of #condensates in common diseases and their related traits. #ASHG23 See the Reviewers’ Choice poster for more details: dewpointx.com/rare-missense-…

At last week’s annual <a href="/GeneticsSociety/">ASHG</a> meeting, Dewpoint scientist <a href="/Ruoyu_Tian/">Ruoyu Tian</a> shared our advances in identifying the role of #condensates in common diseases and their related traits. #ASHG23
See the Reviewers’ Choice poster for more details:
dewpointx.com/rare-missense-…
Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

We are pleased to share Dewpoint CSO Isaac Klein’s Drug Discovery World podcast about the intersection of #condensate science and therapeutic development. Isaac brings his unique perspective as a physician-scientist to solving complex biological puzzles and advancing drug discovery.

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Read our latest Journal of Molecular Biology perspective by Erik Martin, Christiane Iserman, Balaji Olety, Diana Mitrea & Isaac Klein reviewing the role of #condensates in the viral replication cycle and discussing novel strategies to target them for novel antiviral therapies: sciencedirect.com/science/articl…

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Today we announced multiple patent applications on novel composition of matter for the treatment of ALS, “a significant leap forward in our mission to redefine the treatment of diseases deemed intractable or difficult to treat” Read the Press Release: dewpointx.com/dewpoint-thera…

Today we announced multiple patent applications on novel composition of matter for the treatment of ALS, “a significant leap forward in our mission to redefine the treatment of diseases deemed intractable or difficult to treat”
Read the Press Release:
dewpointx.com/dewpoint-thera…
Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Dr. Jesse Lai will present on October 9 at the Society for Neuroscience’s Neuroscience 2024 conference. Join him to find out how a #condensate modulating drug reverses markers of #ALS pathology, by targeting a #condensatopathy shared by ~97% of patients. sfn.org/meetings/neuro…

Dr. <a href="/JesseLai/">Jesse Lai</a> will present on October 9 at the Society for Neuroscience’s Neuroscience 2024 conference. Join him to find out how a #condensate modulating drug reverses markers of #ALS pathology, by targeting a #condensatopathy shared by ~97% of patients. sfn.org/meetings/neuro…
Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Why is Dewpoint Therapeutics One to Watch? Revolutionary #condensate science with applicability across therapeutic areas, an #AI-powered state-of-the-art platform, unrivaled expertise, and a culture that nourishes growth and innovation. thepharmaletter.com/ones-to-watch/…

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Another major milestone for Dewpoint: the nomination of DPTX3186 as the first condensate modulating development candidate, for the treatment of Wnt-driven cancers. DPTX3186 c-mod inhibits the function of a historically ‘undruggable’ target – beta catenin. tinyurl.com/4s49ruve

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Our next Kitchen Table Talk is tomorrow, October 30, with Dragomir Milovanovic, Principal Investigator - Molecular Neuroscience, German Center for Neurodegenerative Diseases. Join us to learn about “Condensate biology at the synapse”. Register here: condensates.com/resources/drag…

Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Great coverage in The Pharma Letter about a major milestone for Dewpoint – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for the treatment of Wnt-driven cancers. Read the article: thepharmaletter.com/major-mileston…

Bappaditya Chandra (@chandralabndsu) 's Twitter Profile Photo

Our lab's latest News & Views in Nature Chemistry analyzes key findings from Thody et al: physicochemical properties, not structure, drive small molecule partitioning into biomolecular condensates. Important implications for drug development! Kriwacki Lab nature.com/articles/s4155…

Our lab's latest News &amp; Views in <a href="/NatureChemistry/">Nature Chemistry</a> analyzes key findings from Thody et al: physicochemical properties, not structure, drive small molecule partitioning into biomolecular condensates. Important implications for drug development!  <a href="/kriwacki/">Kriwacki Lab</a> 

nature.com/articles/s4155…
Dewpoint Therapeutics (@dewpoint_tx) 's Twitter Profile Photo

Announcing the nomination of DPTX3496, the second #cmod development candidate that targets the oncogenic driver function of beta catenin in Wnt-driven cancers. IND-enabling studies are progressing and IND filing is planned for the second half of the year. tinyurl.com/26xde734